Endra Life Sciences INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
ENDRA Life Sciences director Anthony DiGiandomenico has entered into a voting agreement, committing to support a merger with ASP Isotopes Inc. and its subsidiaries.
NASDAQ
SCHEDULE 13D: Director Boosts ENDRA Life Sciences Stake to 9.99%
Anthony DiGiandomenico, a director at ENDRA Life Sciences Inc., has increased his beneficial ownership to 9.99% of the company's common stock.